Ginkgo Biloba Vs Desmopressin in Treatment of Children with Monosymptomatic Nocturnal Enuresis

Menoufia University

Status: Enrolling

Conditions: Nocturnal Enuresis in Children; Monosymptomatic Nocturnal Enuresis; Desmopressin

Treatments: Drug: Desmopressin Acetate 0.2 mg Tablets; Drug: Ginkgo Biloba oral tablet

Study type: Interventional

Funder types: Other

Identifiers

NCT06771128

Ginkgo Biloba vs Desmopressin

Details and patient eligibility

About

the efficacy of Ginkgo Biloba versus desmopressin in treatment of children with monosymptomatic nocturnal enuresis

Full description

Bedwetting among children is a common disorder, affecting 30% at age 4, 10% at age 6, 3% at age 12, and 1% at age. Untreated, the spontaneous cure rate is about 15% a year. Treatment is dominated by two approaches, enuresis alarm and drugs.

Treatment with drugs has largely been focused on tricyclic antidepressants especially imipramine or, more recently, antidiuretic agents such as desmopressin. For imipramine the proportion of total remission is 10-50% during treatment and a long term cure in 5-40%. However, numerous reports of side effects, some lethal, have led to a decline in its use.

One of theory of nocturnal enuresis is deep sleep in children, this the main cornerstone in using Alarm as line of management.

On the other hand drugs used in re-habitation of sleep rhythm seems to be with great benefits in management as GINKGO BILOBA.

Ginkgo biloba leave extract is among the most widely sold herbal dietary supplements in the United States. Its purported biological effects include: scavenging free radical; lowering oxidative stress; reducing neural damages, reducing platelets aggregation; anti-inflammation; anti-tumor activities; anti-aging, and improve night sleep rhythm.

the aim of this study is to evaluate the effect of Ginkgo Biloba versus desmopressin in treatment of children with monosymptomatic nocturnal enuresis.

Enrollment: 90 estimated patients

Sex: All

Ages: 5 to 18 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• all children with monosymptomatic nocturnal enuresis.

Exclusion criteria

• children with day and night wetting.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

90 participants in 3 patient groups

Ginkgo Biloba group

Experimental group

Description:

Patients in this group receive Ginkgo Biloba oral tablet.

Treatment:

Drug: Ginkgo Biloba oral tablet

Desmopressin group

Active Comparator group

Description:

Patients in this group receive Desmopressin oral tablets.

Treatment:

Drug: Desmopressin Acetate 0.2 mg Tablets

Combination group

Experimental group

Description:

Patients in this group receive both Ginkgo Biloba and desmopressin oral tablets.

Treatment:

Drug: Ginkgo Biloba oral tablet

Drug: Desmopressin Acetate 0.2 mg Tablets